Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Acute Myeloid Leukemia
About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Acute myeloid leukemia, Homoharringtonie, Azacitidine, Demethylation
Eligibility Criteria
Inclusion Criteria:
- Diagnoised with acute myeloid leukemia
- Meet the criteria of the 2016 WHO classification system(APL were excluded), based on blood cell counting, bone marrow biopsy, and cytogeneic diagnosis
- Volunteered to sign the informed consent.
Exclusion Criteria:
- Mental disorders or other conditions that cannot meet the requirements of research, treatment and monitoring
- Uncontrolled cardiovascular disease
- Allergic to azacytarine, homoharringtonie, or other drugs of this study
- Any other conditions considered by the study investgators that are not suitable for participating in this clinical trial.
Sites / Locations
- Department of Hematology, Zhongda Hospital, Medical School of Southeast UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Azacitidine plus HAG
Azacitidine plus HIA
Azacitidine plus HDA
Patients of de novo or relapsed AML(age≥60y or ineligibility to receive intensive chemotherapy) will receive AZA+HAG (homoharringtonie, cytarabine, G-CSF) regiment as induction therapy. After complete remission(CR), the AZA+HAG regimen was further given 4-6 cycles and followed by azacitidine maintenance or until the disease progresses. AZA -Azacitidine HAG -Homoharringtonie, Cytarabine, G-CSF
Patients of de novo or relapsed AML(age<60y or eligible for intensive chemotherapy) will receive AZA +HIA(homoharringtonie, Idarubicin, cytarabine) regiments as introduction therapy. After CR, post-remission therapy will follow with NCCN guidelines. AZA -Azacitidine HIA -Homoharringtonie, Cytarabine, Idarubicin
Patients of de novo or relapsed AML(age<60y or eligible for intensive chemotherapy) will receive AZA +HDA(homoharringtonie, daunorubicin, cytarabine) regiments as introduction therapy., After CR, post-remission therapy will follow with NCCN guidelines. AZA -Azacitidine HDA -Homoharringtonie, Cytarabine, Daunorubicin